Eli Lilly Stock Jumps on Obesity Drug's FDA Approval
The Eli Lilly drug, which will be marketed as an obesity treatment under the name Zepbound, is already sold as a diabetes treatment named Mounjaro.
Source: marketwatch.com
Page 16 - Daniel Acker Bloomberg News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Daniel Acker Bloomberg. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Daniel Acker Bloomberg Today - Breaking & Trending Today
D.R. Horton Beats Estimates, Hikes Dividend. The Home Builder's Outlook Is Good.
D.R. Horton reports earnings and revenue ahead of analysts' expectations and raises its quarterly dividend to 30 cents a share.
Source: marketwatch.com
Is There Actually Any Pumpkin In Canned Pumpkin?
It’s time to squash the rumors for good.
Source: huffingtonpost.co.uk
D.R. Horton Is a Housing Bellwether. What Earnings Could Predict.
The big residential builder reports earnings on Tuesday.
Source: marketwatch.com
Estée Lauder Stock Falls Sharply After Outlook Cut on China Pains
Cosmetics company Estée Lauder cut its fiscal-year outlook as headwinds in China are expected to persist.
Source: marketwatch.com